GCDx is not calling their test DR-70 or Onko-Sure. So the trademarks and names are moot.
The patent application was rejected twice. Now it's being reviewed again by the same examiner. Did Radient get their act together this time? Flip of the coin, IMO.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.